CA3096575C - COMBINATION CONTAINING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND - Google Patents

COMBINATION CONTAINING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND

Info

Publication number
CA3096575C
CA3096575C CA3096575A CA3096575A CA3096575C CA 3096575 C CA3096575 C CA 3096575C CA 3096575 A CA3096575 A CA 3096575A CA 3096575 A CA3096575 A CA 3096575A CA 3096575 C CA3096575 C CA 3096575C
Authority
CA
Canada
Prior art keywords
zidovudine
combination
antimicrobial compound
pharmaceutically acceptable
acceptable derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3096575A
Other languages
English (en)
French (fr)
Other versions
CA3096575A1 (en
Inventor
Anthony Coates
Yanmin Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helperby Therapeutics Ltd
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Publication of CA3096575A1 publication Critical patent/CA3096575A1/en
Application granted granted Critical
Publication of CA3096575C publication Critical patent/CA3096575C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3096575A 2018-04-30 2019-04-12 COMBINATION CONTAINING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND Active CA3096575C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1807046.6A GB201807046D0 (en) 2018-04-30 2018-04-30 Combination
GB1807046.6 2018-04-30
PCT/GB2019/051062 WO2019211576A1 (en) 2018-04-30 2019-04-12 Combination comprising zidovudine and an antimicrobial compound

Publications (2)

Publication Number Publication Date
CA3096575A1 CA3096575A1 (en) 2019-11-07
CA3096575C true CA3096575C (en) 2025-02-04

Family

ID=62494998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096575A Active CA3096575C (en) 2018-04-30 2019-04-12 COMBINATION CONTAINING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND

Country Status (8)

Country Link
US (1) US11951119B2 (enExample)
EP (1) EP3787622B1 (enExample)
JP (2) JP7412008B2 (enExample)
CN (1) CN112218633A (enExample)
CA (1) CA3096575C (enExample)
GB (1) GB201807046D0 (enExample)
PL (1) PL3787622T3 (enExample)
WO (1) WO2019211576A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913068D0 (en) * 2019-09-10 2019-10-23 Helperby Therapeutics Ltd Combination
CN114196586B (zh) * 2021-12-20 2023-04-11 郑州大学 一株蒙氏肠球菌及其在发酵中草药中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028074A1 (en) 1998-11-09 2000-05-18 St. George's Enterprises Limited Screening process for antibacterial agents
US6521270B1 (en) 2001-06-11 2003-02-18 The Procter & Gamble Company Compositions comprising nitrofurantoin and uva ursi
US7410974B2 (en) 2003-08-08 2008-08-12 Ulysses Pharmaceutical Products, Inc. Halogenated Quinazolinyl nitrofurans as antibacterial agents
JP2005239696A (ja) * 2004-01-30 2005-09-08 Daiichi Suntory Pharma Co Ltd 無機物質を配合した医薬硬質カプセル剤
US20080226614A1 (en) * 2004-08-23 2008-09-18 Krishna Murthy Ella Eukaryotic Based Synergistic Formulation for Gastro-Intestinal Disorders
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB201305277D0 (en) 2013-03-22 2013-05-01 Helperby Therapeutics Ltd Novel combination and use
GB201401617D0 (en) 2014-01-30 2014-03-19 Helperby Therapeutics Ltd Novel combination and use
DE102014218913A1 (de) * 2014-09-19 2016-03-24 Heraeus Medical Gmbh Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver
GB201521771D0 (en) 2015-12-10 2016-01-27 Helperby Therapeutics Ltd Formulation
GB201612093D0 (en) 2016-07-12 2016-08-24 Helperby Therapeutics Ltd Combination

Also Published As

Publication number Publication date
EP3787622A1 (en) 2021-03-10
EP3787622B1 (en) 2023-12-13
CA3096575A1 (en) 2019-11-07
CN112218633A (zh) 2021-01-12
PL3787622T3 (pl) 2024-05-20
JP2021522292A (ja) 2021-08-30
JP7412008B2 (ja) 2024-01-12
JP7577376B2 (ja) 2024-11-05
JP2024009968A (ja) 2024-01-23
EP3787622C0 (en) 2023-12-13
WO2019211576A1 (en) 2019-11-07
GB201807046D0 (en) 2018-06-13
US11951119B2 (en) 2024-04-09
US20220117991A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
MX2020005772A (es) Composiciones que comprenden cepas bacterianas.
HK1254843A1 (en) Compositions comprising bacterial strains
HK1254843B (zh) 包含细菌菌株的组合物
WO2017106957A8 (en) Lipid-linked prodrugs
MX2020003581A (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas.
EP4570392A3 (en) Coatings
WO2016100578A3 (en) Antimicrobial polymyxins for treatment of bacterial infections
EP4327876A3 (en) Immunogenic compositions
EP4046564A4 (en) ENDOSCOPE SYSTEM
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
EP3941381A4 (en) VENTILATED ENDOSCOPE TRAY COVERS, SYSTEMS AND PROCESSES
EP3979493A4 (en) OPERATIONAL ENHANCEMENT
EP4085955A4 (en) MEDICAL VENTILATION SYSTEM
CA3096575C (en) COMBINATION CONTAINING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND
WO2018187623A8 (en) Crystalline forms of (s)-afoxolaner
EP3890731A4 (en) COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
WO2018211324A8 (en) Prodrugs for the treatment of disease
GEP20247590B (en) Antibacterial quinolines
WO2019141999A8 (en) Combination therapy for treating or preventing cancer
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
WO2019136310A3 (en) Novel compounds for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240320

EEER Examination request

Effective date: 20240320

EEER Examination request

Effective date: 20240320

EEER Examination request

Effective date: 20240320